An Open-label Phase 1 of Pembrolizumab in Combination With Bevacizumab and Pegylated Liposomal Doxorubicin in Patients With Platinum Resistant Epithelial Ovarian Cancer

Trial ID # NCT03596281
Phase I
Drug Class Angiogenesis Inhibitors: VEGF
Drug Name Bevacizumab
Alternate Drug Names immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin
Drugs in Trial Bevacizumab, Liposomal doxorubicin, Pembrolizumab
Eligible Participant

Platinum resistant or refractory ovarian cancer

Patients Enrolled

22 patients, median 3 prior therapies (1-13), 41% primary Pt-R, 82% w/ prior Bev, 41% w/ prior PARPi

Therapy Setting

Recurrence

Study Design

Open-Label, Non-randomized

Endpoints

CBR, ORR, DCR, evaluated per RECIST

Efficacy

ORR: 32% (6PR, n=19)
DCR: 74% (6PR, 8SD, n=19)
CBR: 53%

Conclusion

Bevacizumab+liposomal doxorubicin+pembrolizumab is well tolerated and demonstrate durable responses in platinum resistant ovarian cancer patients

Reference

Michels J et al. Pembrolizumab in combination with bevacizumab and pegylated liposomal doxorubicin in patients with platinum-resistant epithelial ovarian cancer. J Clin Oncol (2021) 39 (suppl 15; abstr 5522)
https://meetinglibrary.asco.org/record/195554/abstract

Michels J et al. Poster
https://www.clearityfoundation.org/wp-content/uploads/2021/06/PemDoxilBev-Poster-ASCO-2021-scaled.jpeg

Contact Us
Contact Us

We are here to help! Send us a message below or give us a call at (858) 657-0282.